

HOSPITALISTS' PERSPECTIVES ON OPTIMIZING BASAL INSULIN IN TYPE 2 DIABETES:

Evaluating Current and Emerging Therapies and Their
Impact on Therapeutic Inertia and Transitions of Care



Suggested Readings

Diabetes Care in the Hospital and Clinical Inertia

American Diabetes Association. Overcoming Therapeutic Inertia.
<https://www.therapeuticinertia.diabetes.org/>

Drincic AT, Akkireddy P, Knezevich JT. Common models used for inpatient diabetes management. *Curr Diab Rep*. 2018;18:10. doi: [10.1007/s11892-018-0972-x](https://doi.org/10.1007/s11892-018-0972-x). PMID: 29442175.

Drincic A, Pfeiffer E, Luo J, et al. The effect of diabetes case management and Diabetes Resource Nurse program on readmissions of patients with diabetes mellitus. *J Clin Transl Endocrinol*. 2017;8:29-34. doi: [10.1016/j.jcte.2017.03.003](https://doi.org/10.1016/j.jcte.2017.03.003)

Knezevich JT, Donihi AC, Drincic AT. Pharmacist role in providing inpatient diabetes management. *Curr Diab Rep*. 2022;22:441-449. doi: [10.1007/s11892-022-01487-8](https://doi.org/10.1007/s11892-022-01487-8)

Korytkowski MT, Muniyappa R, Antinori-Lent K, et al. Management of hyperglycemia in hospitalized adult patients in non-critical care settings: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2022;107:2101-2128. doi: [10.1210/clinem/dgac278](https://doi.org/10.1210/clinem/dgac278)

Miles E, McKnight M, Schmitz CC, et al. Developing a diabetes discharge order set for patients with diabetes on insulin. *J Diabetes Sci Technol*. 2024;18:570-576. doi: [10.1177/19322968241239621](https://doi.org/10.1177/19322968241239621)

Mubeen F, Low Wang CC, Al Maradni A, et al. Digital health and shared decision-making in diabetes care – a survey initiative in patients and clinicians. *Endocr Pract*. 2023;29:538-545. doi: [10.1016/j.eprac.2023.04.012](https://doi.org/10.1016/j.eprac.2023.04.012)

Pasquel FJ, Lansang MC, Dhatariya K, et al. Management of diabetes and hyperglycaemia in the hospital. *Lancet Diabetes Endocrinol*. 2021;9:174-188. doi: [10.1016/S2213-8587\(20\)30381-8](https://doi.org/10.1016/S2213-8587(20)30381-8)

Pasquel FJ, Umpierrez GE. Web exclusive. Annals for Hospitalists Inpatient Notes – How we treat hyperglycemia in the hospital. *Ann Intern Med*. 2021;174:HO2-HO4. doi: [10.7326/M21-2789](https://doi.org/10.7326/M21-2789)

Pichardo-Lowden AR. Clinical decision support for diabetes care in the hospital: a time for change toward improvement of management and outcomes. *J Diabetes Sci Technol*. 2021;16:771-774. doi: [10.1177/1932296820982661](https://doi.org/10.1177/1932296820982661)

Polavarapu P, Pachigolla S, Drincic A. Glycemic management of hospitalized patients receiving nutrition support. *Diabetes Spectr*. 2022;35:427-439. doi: [10.2337/dsi22-0010](https://doi.org/10.2337/dsi22-0010)

Weekly/Long-Acting Insulin

Bajaj HS, Goldenberg RM. Insulin icodec weekly: a basal insulin analogue for type 2 diabetes. *touchREV Endocrinol.* 2023;19:4-6. doi:[10.17925/EE.2023.19.1.4](https://doi.org/10.17925/EE.2023.19.1.4)

Kjeldsen TB, Hubálek F, Hjørringgaard CU, et al. Molecular engineering of insulin icodec, the first acylated insulin analog for once-weekly administration in humans. *J Med Chem.* 2021;64:8942-8950. doi:[10.1021/acs.jmedchem.1c00257](https://doi.org/10.1021/acs.jmedchem.1c00257)

Lingvay I, Asong M, Desouza C, et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes: the ONWARDS 3 randomized clinical trial. *JAMA.* 2023;330:228-237. doi:[10.1001/jama.2023.11313](https://doi.org/10.1001/jama.2023.11313)

Philis-Tsimikas A, Bajaj HS, Begtrup K, et al. Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes. *Diabetes Obes Metab.* 2023;25:331-341. doi: [10.1111/dom.14871](https://doi.org/10.1111/dom.14871)

Pieber TR, Asong M, Fluhr G, et al. Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 2 diabetes. *Diabetes Obes Metab.* 2023;25:3716-3723. doi:[10.1111/dom.15266](https://doi.org/10.1111/dom.15266)

Wysham C, Bajaj HS, Del Prato S, et al. Insulin efsitora versus degludec in type 2 diabetes without previous insulin treatment. *N Engl J Med.* 2024. doi: [10.1056/NEJMoa2403953](https://doi.org/10.1056/NEJMoa2403953)